Table 3:

Multiple regression analysis of clinical factors, PAM50 subtype, each TCGA-validated miRNA and breast cancer outcomes in the WHEL-genomics breast cancer substudy

Predictors	Disease free survival (N=295 relapse events)*	Breast cancer survival (N=212 breast cancer deaths)*	Overall survival (N=306 deaths)*
	HR (95% CI)	HR (95% CI)	HR (95% CI)
Model for miRNA-210
Tumor Stage
I (Ref) IIA IIB IIIA IIIC	1.0 1.72 (1.24, 2.38) 2.47 (1.67, 3.65) 3.52 (2.46, 5.02) 4.00 (2.52, 6.36)	1.0 1.90 (1.25, 2.89) 3.09 (1.92, 4.97) 4.52 (2.92, 7) 6.26 (3.7, 10.6)	1.0 1.26 (0.93, 1.71) 1.83 (1.26, 2.65) 2.36 (1.67, 3.33) 3.75 (2.44, 5.77)
PAM50 Subtype
Luminal A (Ref) Basal Her2 Luminal B	1.0 1.14 (0.79, 1.65) 0.91 (0.60, 1.39) 1.55 (1.16, 2.08)	1.0 0.94 (0.6, 1.47) 0.86 (0.52, 1.42) 1.64 (1.17, 2.31)	1.0 0.9 (0.61, 1.32) 0.97 (0.64, 1.45) 1.58 (1.2, 2.09)
MiRNA 210	1.09 (1, 1.2)	1.07 (0.96, 1.19)	1.04 (0.95, 1.13)
Model for miRNA-29c
Tumor Stage
I (Ref) IIA IIB IIIA IIIC	1.0 1.73 (1.25, 2.4) 2.47 (1.67, 3.65) 3.37 (2.35, 4.82) 3.95 (2.48, 6.3)	1.0 1.87 (1.23, 2.85) 3.05 (1.89, 4.92) 4.27 (2.75, 6.62) 6.05 (3.57, 10.26)	1.0 1.24 (0.92, 1.68) 1.8 (1.24, 2.61) 2.25 (1.59, 3.17) 3.61 (2.35, 5.56)
PAM50 Subtype
Luminal A (Ref) Basal Her2 Luminal B	1.0 1.36 (0.92, 2.0) 1.01 (0.66, 1.54) 1.58 (1.18, 2.12)	1.0 1.23 (0.77, 1.97) 0.99 (0.6, 1.62) 1.66 (1.18, 2.32)	1.0 1.13 (0.75, 1.7) 1.08 (0.72, 1.63) 1.58 (1.2, 2.09)
MiRNA 29c	1.08 (0.95, 1.22)	1.17 (1.01, 1.37)	1.16 (1.02, 1.31)

^*Models also adjusted for age at diagnosis, grade; Patients with a Normal PAM50 subtype were excluded.